12:00 AM
 | 
Apr 28, 2016
 |  BC Innovations  |  Translation in Brief

Second chance for grantees

Leidos promises a second life for unfunded NIH proposals

NIH has launched a pilot program with Leidos Holdings Inc. (NYSE:LDOS) to answer the question: is there life after grant rejection?

The academic community has long groused about funding limitations through NIH, and even with the $2 billion increase in funding for FY16, many highly scored grant proposals get underfunded or passed over altogether. With initial backing from NIH, Leidos developed the Online Partnership to Accelerate Research (OnPAR), a pilot tool to connect researchers who have strong, but NIH-rejected,...

Read the full 376 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >